About 25% of NAFLD patients progress to a more severe stage including liver inflammation (nonalcoholic steatohepatitis, NASH) and scarring (liver fibrosis), which can lead to cirrhosis or even liver ...

Non-alcoholic fatty liver disease (NAFLD) represents the most common liver disease worldwide affecting approximatively 20–30% ...

The pharmacologic agents used in treating NAFLD include insulin-modulating, lipid-modulating, fibrosis-modulating and oxidative stress-modulating therapies. At present, Vitamin E can be ...

In the early stages, fatty liver may be asymptomatic, with most people unaware they have it. However, continued fat buildup ...

Liver fibrosis is a major global health concern, developing as a result of chronic liver diseases (CLDs) such as viral hepatitis, alcohol-related liver disease, and non-alcoholic fatty liver disease ...

Apart from consumption causes, hepatitis B (HBV) and hepatitis C (HCV) viruses can cause liver fibrosis without the preceding fatty liver stages. Medications such as non-steroidal anti ...

Resmetirom offers a targeted approach to metabolic dysfunction–associated steatohepatitis (MASH) for use alongside lifestyle ...

About 25% of NAFLD patients progress to a more severe stage including liver inflammation (nonalcoholic steatohepatitis, NASH) and scarring (liver fibrosis), which can lead to cirrhosis or even ...

Metabolic dysfunction-associated fatty liver disease (MAFLD) has become a growing global health concern, affecting millions ...

About 25% of NAFLD patients progress to a more severe stage including liver inflammation (nonalcoholic steatohepatitis, NASH) and scarring (liver fibrosis), which can lead to cirrhosis or even ...